New bladder cancer therapy shows promise in early trial
NCT ID NCT06253845
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 22 times
Summary
This study tests a new drug called CG0070 in 20 people with intermediate-risk bladder cancer that hasn't spread into the muscle. After surgery to remove visible tumors, patients receive CG0070 to see if it is safe and helps prevent the cancer from coming back. The goal is to control the disease and reduce recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON MUSCLE INVASIVE BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.